Solid Carcinomas of the Exocrine Pancreas

Cruickshank, A. H.

doi:10.1007/978-1-4471-3329-2_8

Cited by 3 publications

(3 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor desmoplasia in pancreatic cancer an advanced stage, and a limited response to chemotherapy and radiotherapy [1,2]. In addition, an intense fibrotic reaction known as tumor desmoplasia is characteristic for PDAC [3]. The histopathologic finding in pancreas adenocarcinomas are infiltrating carcinoma cells, which are surrounded by a dense fibroblastic stroma consisting primarily of collagen types I and III and fibronectin [4].…”

Section: Introductionmentioning

confidence: 98%

Pancreatic stellate cells—role in pancreas cancer

Bachem

Zhou

Buck

et al. 2008

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Pancreatic stellate cells—role in pancreas cancer

Bachem

Zhou

Buck

et al. 2008

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…A hallmark of PDA is the intense fibrotic reaction around the tumor cells known as the 'desmoplatic' reaction (DR). This arises from complex interactions between the tumor cells and surrounding stroma which is composed of fibroblast, endothelial cells, extracellular matrix (ECM) and infiltrating inflammatory cells [40]. This cellular complexity coupled to the myriad of elaborated growth factors (e.g.…”

Section: Target Selection For Mab-based Thera-piesmentioning

confidence: 99%

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Engelhardt¹,

Riley²,

Cooke³

et al. 2006

CDDT

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with a poor prognosis where incidence mirrors mortality. Gemcitabine and gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) are the only FDA approved therapies for unresectable or metastatic PDA and are at best palliative. Hence, considerable efforts have been initiated to identify novel targets for monoclonal antibody (Mab) therapies that may safely and effectively be combined with gemcitabine. Mabs to cell surface receptors and/or their ligands have shown efficacy in pre-clinical and clinical studies in both solid and hematological malignancies and can safely be given with chemotherapy. A number of clinical trials have evaluated the safety and efficacy of Mabs targeting the tumor and/or tumor micro-environment and in combination with chemotherapy for PDA with very little success. Here we review the rationale for Mab therapies, targeted clinical trials, rational basis for target selection, pre-clinical models and promising novel cell surface targets and/or growth factor ligands that are amenable to ongoing and future Mab therapies that hold promise and hope for patients and their families with this devastating disease.

show abstract

“…Furthermore, malignant cells were seen to invade into the interstitial matrix with exposure to collagen. The DR is associated with an abnormal vasculature with capillary leakage leading to a release of growth factors, e.g., transforming growth factor beta (TGFß) [1]. In addition, an important role of the tumor microenvironment (TME) in tumor development was demonstrated by releasing ECM modulating factors, such as matrix metalloproteinase-3 (activates Rac1b), integrin (activates Rho), or matriptase (activates phosphatidylinositol 3-kinase/Akt) [2][3][4].…”

Section: Introductionmentioning

confidence: 99%